title: [A case of hypersensitivity reaction to reintroduced-oxaliplatin at the second course of oxaliplatin-based chemotherapy after neoadjuvant chemotherapy for liver metastases from colon cancer].
abstract: As chemotherapy advances, patients who had liver metastases often come to receive liver resection after their chemotherapy, including oxaliplatin-based chemotherapy. We experienced a case of an acute hypersensitivity reaction to reintroduced-oxaliplatin at the second course of oxaliplatin-based adjuvant chemotherapy, after neoadjuvant chemotherapy for liver metastases originating from colon cancer. There is a report that hypersensitivity reactions are frequent in the second course of the reintroduced-oxaliplatin-based regimen. It is thought that the prevention is necessary at the second course even if there is no significant symptom at the first course. Similar cases will increase as neoadjuvant therapies spread in the future; therefore, prescriptions for preventing hypersensitivity are necessary when administering reintroduced-oxaliplatin base chemotherapy.
authors.affiliation: Integrated Surgery and Oncology, Tohoku University Graduate School of Medicine.
authors.forename: Yu
authors.initials: Y
authors.lastname: Katayose
authors.forename: Kei
authors.initials: K
authors.lastname: Nakagawa
authors.forename: Tohru
authors.initials: T
authors.lastname: Onogawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yoshida
authors.forename: Fuyuhiko
authors.initials: F
authors.lastname: Motoi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Naitoh
authors.forename: Toshiki
authors.initials: T
authors.lastname: Rikiyama
authors.forename: Shinichi
authors.initials: S
authors.lastname: Egawa
authors.forename: Michiaki
authors.initials: M
authors.lastname: Unno
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004342:Drug Hypersensitivity; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D020360:Neoadjuvant Therapy; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin